Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

$24.99

Economic Value Added (EVA)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Bristol-Myers Squibb Co., economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The financial data reveals notable fluctuations in key performance metrics over the five-year period analyzed. The net operating profit after taxes (NOPAT) demonstrates significant volatility, moving from a substantial negative figure in the initial year to positive values in the middle years, before declining sharply once again in the final year. Specifically, NOPAT starts with a considerable loss, improves to positive territory, decreases somewhat subsequently, shows recovery in 2023, and then falls back to a pronounced negative value in 2024.

The cost of capital exhibits a generally upward trend from the start of the period, rising from approximately 7.26% to 8.02% by the end of 2022, followed by a slight decline and stabilization around 7.5% in the last two years. This increase suggests rising costs associated with funding and investment risk during the earlier half of the period, before settling somewhat in recent years.

Invested capital consistently declines across all years analyzed, decreasing from over 90 billion US dollars to approximately 62.7 billion US dollars by the end of 2024. This trend indicates a reduction in the capital employed by the company, which could reflect strategic divestitures, asset sales, or efforts to optimize capital structure.

Economic profit, which measures the value created above the cost of capital, mirrors the volatility observed in NOPAT but with higher sensitivity given its integration of invested capital and cost of capital. Economic profit starts with a significant negative value, improves to a marginally positive figure in 2021, drops back into negative territory in 2022, recovers slightly in 2023, and then declines sharply again in the final year. This pattern suggests that the company struggled to consistently generate returns exceeding its cost of capital, with performance peaking mid-period but deteriorating notably by 2024.

Summary of Trends

The period is characterized by operational profitability challenges and a diminishing investment base. Despite some recovery phases, profitability as measured by NOPAT and economic profit does not show a stable upward trajectory, underscoring intermittent difficulties in value creation.

Cost of Capital

An upward trend in the initial years followed by stabilization suggests fluctuating but manageable financing costs, potentially reflecting changing market conditions or risk perceptions.

Invested Capital

The steady decrease points to a significant restructuring or strategic capital management, possibly aimed at improving efficiency or reallocating resources.

Performance Implications

The erratic economic profit highlights challenges in sustaining returns above the cost of capital, raising concerns about long-term value creation and operational effectiveness during the later periods.


Net Operating Profit after Taxes (NOPAT)

Bristol-Myers Squibb Co., NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net earnings (loss) attributable to BMS
Deferred income tax expense (benefit)1
Increase (decrease) in allowance for expected credit loss2
Increase (decrease) in restructuring liability3
Increase (decrease) in equity equivalents4
Interest expense
Interest expense, operating lease liability5
Adjusted interest expense
Tax benefit of interest expense6
Adjusted interest expense, after taxes7
(Gain) loss on marketable securities
Investment income, before taxes
Tax expense (benefit) of investment income8
Investment income, after taxes9
Net income (loss) attributable to noncontrolling interest
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in allowance for expected credit loss.

3 Addition of increase (decrease) in restructuring liability.

4 Addition of increase (decrease) in equity equivalents to net earnings (loss) attributable to BMS.

5 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

6 2024 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

7 Addition of after taxes interest expense to net earnings (loss) attributable to BMS.

8 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

9 Elimination of after taxes investment income.


Net Earnings (Loss) Attributable to BMS
The net earnings exhibit significant volatility over the five-year period. In 2020, the company experienced a substantial loss of approximately $9.015 billion. This was followed by a strong recovery in 2021, with net earnings turning positive at around $6.994 billion. The positive trend continued through 2022 and 2023, with earnings of $6.327 billion and $8.025 billion, respectively, indicating operational improvements and profitability restoration. However, in 2024, the net earnings again declined sharply to a loss of about $8.948 billion, suggesting potential one-time charges, operational challenges, or market conditions adversely affecting profitability.
Net Operating Profit After Taxes (NOPAT)
The NOPAT values reflect a similar pattern of volatility as net earnings. In 2020, the company reported a significant negative NOPAT of approximately $6.822 billion. The following year showed a substantial positive turnaround with NOPAT reaching $6.656 billion. Despite this improvement, the subsequent years showed a decline in NOPAT, falling to $4.571 billion in 2022 and recovering slightly to $5.869 billion in 2023. In 2024, there was a notable decline to a negative $9.292 billion, aligning with the net earnings loss. This suggests that operational efficiency and tax impacts fluctuated considerably, with a sharp deterioration in 2024 likely driven by operational issues or exceptional expenses.
Overall Trend and Insights
Both net earnings and NOPAT demonstrate a pronounced cyclical pattern, with strong losses in 2020 followed by recovery in the subsequent years up to 2023, and then a substantial reversal back to losses in 2024. This pattern indicates that while the company was able to restore profitability after a difficult 2020, it encountered renewed challenges in 2024. The divergence between earnings and operating profit in some years suggests that non-operating factors, such as extraordinary items or tax effects, may have influenced net profitability. The data points to the necessity for a deeper review of underlying causes behind the 2024 downturn, including potential one-time charges, market dynamics, or changes in operational efficiency.

Cash Operating Taxes

Bristol-Myers Squibb Co., cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Income tax provision
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Income Tax Provision
The income tax provision shows a fluctuating trend over the five-year period. Starting at 2,124 million US dollars in 2020, it declined significantly to 1,084 million in 2021, followed by a moderate increase to 1,368 million in 2022. In the subsequent years, the provision dropped sharply to 400 million in 2023 but experienced a slight rebound to 554 million in 2024. This pattern suggests variability in taxable income or changes in tax strategy or regulations impacting the provision calculation.
Cash Operating Taxes
Cash operating taxes display a different trajectory compared to income tax provisions, indicating potential timing differences or other tax-related factors. The amount nearly doubled from 1,445 million in 2020 to 2,764 million in 2021, followed by a further substantial increase to 4,376 million in 2022. However, in 2023, cash operating taxes declined to 3,947 million and continued to drop to 3,068 million in 2024. Despite the reductions in recent years, cash tax payments remain significantly higher than in 2020. This trend may reflect changes in cash flow management, tax payment scheduling, or adjustments related to tax liabilities and credits.
Overall Insights
The divergence between income tax provision and cash operating taxes is notable. While income tax provisions generally decreased over the period with some volatility, cash operating taxes rose sharply before declining in the last two years but still remained elevated relative to 2020. These contrasting patterns could indicate differences in accounting recognition of tax expenses versus actual cash outflows. The fluctuations in both indicators highlight the importance of analyzing tax-related cash impacts separately from accounting provisions to fully understand the company's tax position and its effect on liquidity and profitability.

Invested Capital

Bristol-Myers Squibb Co., invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Short-term debt obligations
Long-term debt, excluding current portion
Operating lease liability1
Total reported debt & leases
Total BMS shareholders’ equity
Net deferred tax (assets) liabilities2
Allowance for expected credit loss3
Restructuring liability4
Equity equivalents5
Accumulated other comprehensive (income) loss, net of tax6
Noncontrolling interest
Adjusted total BMS shareholders’ equity
Construction in progress7
Marketable debt securities and equity investments8
Invested capital

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of allowance for doubtful accounts receivable.

4 Addition of restructuring liability.

5 Addition of equity equivalents to total BMS shareholders’ equity.

6 Removal of accumulated other comprehensive income.

7 Subtraction of construction in progress.

8 Subtraction of marketable debt securities and equity investments.


Total reported debt & leases
There is a noticeable reduction in total reported debt and leases from 2020 to 2022, falling from approximately $51.7 billion to about $40.7 billion. However, the debt level stabilizes around $41.5 billion in 2023 before increasing significantly to $51.2 billion in 2024, approaching the 2020 debt level once again.
Total BMS shareholders’ equity
The shareholders’ equity shows a consistent declining trend over the five-year period. Starting at around $37.8 billion in 2020, it decreases gradually each year, falling to roughly $16.3 billion in 2024. This decline is particularly pronounced between 2023 and 2024, where equity drops by nearly 45%, indicating potential challenges impacting the company’s net worth.
Invested capital
Invested capital follows a downward trend over the period, beginning at approximately $90.1 billion in 2020 and decreasing steadily every year to around $62.7 billion in 2024. The continuous reduction suggests contraction in the company's asset base or potential divestitures and may relate to the simultaneously falling equity and fluctuating debt levels.

Cost of Capital

Bristol-Myers Squibb Co., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Bristol-Myers Squibb Co., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The financial data reveals fluctuating economic profit values over the observed five-year period, indicating inconsistent profitability relative to the capital invested. Initially, the economic profit was significantly negative, improving to a small positive figure in the second year. However, this improvement was not sustained as the figure declined back to negative the following year, followed by another positive result, and then a pronounced negative value in the last year.

The invested capital shows a consistent downward trend throughout the period, decreasing steadily year over year. This may reflect asset sales, depreciation, or a deliberate strategy to reduce capital employed in the business.

The economic spread ratio, which represents the difference between the return on invested capital and the cost of capital, mirrors the fluctuations seen in economic profit. It transitions from a strongly negative position to slightly positive values in the middle years, before settling into a sharply negative figure in the final year. This ratio highlights that the company struggled to generate returns above its cost of capital for most of the period examined, with short-lived exceptions.

Economic Profit
Shows high volatility including both positive and negative values, indicating inconsistency in value creation relative to capital employed.
Invested Capital
Exhibits a continuous decline, suggesting a reduction in capital investment or asset base over the five years.
Economic Spread Ratio
Fluctuates between negative and slightly positive percentages, implying variable success in covering the cost of capital, with a significant deterioration at the end of the period.

Overall, the company's ability to generate economic profit and achieve returns exceeding its cost of capital appears challenged. The persistent downtrend in invested capital does not correspond with steady improvements in economic profitability, pointing to operational or market difficulties that may be impacting financial performance.


Economic Profit Margin

Bristol-Myers Squibb Co., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Revenues
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Revenues
= 100 × ÷ =

3 Click competitor name to see calculations.


Revenue Trends
The revenue figures demonstrate moderate fluctuations over the observed periods. Starting at approximately 42.5 billion US dollars, revenues increased to nearly 46.4 billion in the subsequent year. This was followed by a slight decline to around 46.2 billion, then a further reduction to 45 billion, before rising again to reach approximately 48.3 billion by the final period. Overall, revenues exhibit a pattern of modest growth punctuated by minor decreases.
Economic Profit Analysis
Economic profit reveals a highly variable pattern across the years. It commenced with a substantial negative value of approximately -13.4 billion US dollars, improved dramatically to a positive figure near 548 million in the following year, then reverted back to a negative value of around -1.18 billion. The next year showed a return to positive economic profit, approximately 783 million, before declining sharply to about -14 billion. This volatility indicates significant fluctuations in profitability and value generation relative to the cost of capital.
Economic Profit Margin Assessment
The economic profit margin mirrors the erratic pattern observed in economic profit figures. Initially, the margin was deeply negative at about -31.44%, moved to a small positive margin slightly above 1%, decreased again into negative territory at -2.56%, then rose to a positive 1.74%, before falling steeply back to nearly -29.05% in the latest period. This suggests inconsistent efficiency in generating economic profit relative to revenues.
Overall Insights
The financial data indicate that the company experiences significant swings in its economic profitability despite relatively stable revenue streams. While revenues have grown modestly over the timeframe, economic profit and its margin have fluctuated dramatically, signaling challenges in sustaining value creation. The recurrent shifts between positive and negative economic profit suggest potential issues such as variable cost management, changing investment returns, or other operational factors impacting overall economic performance.